CollabRx (CLRX) climbs higher before the bell after announcing genetic diagnostics firm...

|By:, SA News Editor

CollabRx (CLRX) climbs higher before the bell after announcing genetic diagnostics firm Sengenics will incorporate CLRX's interpretive analytics into its cancer diagnostic tests. Shares +10.75% premarket.